HC Wainwright Issues Optimistic Estimate for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at HC Wainwright upped their FY2026 EPS estimates for Harrow in a research note issued on Wednesday, November 11th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.40) per share for the year, up from their prior estimate of ($0.57). The consensus estimate for Harrow’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Harrow’s Q2 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.92 EPS and FY2027 earnings at $0.50 EPS.

A number of other brokerages have also commented on HROW. Wall Street Zen upgraded Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Leerink Partners started coverage on Harrow in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective for the company. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Friday, October 16th. Finally, BTIG Research reiterated a “buy” rating and set a $63.00 target price on shares of Harrow in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $66.20.

Harrow Price Performance

Harrow stock opened at $28.30 on Friday. The company has a current ratio of 2.29, a quick ratio of 2.08 and a debt-to-equity ratio of 10.15. Harrow has a 12 month low of $25.76 and a 12 month high of $54.85. The stock has a 50-day moving average price of $30.94 and a two-hundred day moving average price of $37.59.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.06. The company had revenue of $99.30 million for the quarter, compared to the consensus estimate of $98.59 million. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%.

Institutional Trading of Harrow

Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV bought a new position in Harrow during the 1st quarter worth $31,000. Sterling Capital Management LLC grew its position in shares of Harrow by 836.8% in the 3rd quarter. Sterling Capital Management LLC now owns 1,068 shares of the company’s stock valued at $33,000 after buying an additional 954 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Harrow in the 3rd quarter valued at about $59,000. First Bancorp Inc ME bought a new stake in shares of Harrow in the 2nd quarter valued at about $64,000. Finally, State of Wyoming acquired a new stake in shares of Harrow in the second quarter valued at about $72,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.